Daniel J Walden - JoVE Visualize

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

The Oncologist|June 6, 2019

A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal CancerMohamad Bassam Sonbol, Raed Benkhadra, Zhen Wang, et al.

Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2023

Changes in Prescribing Patterns in Stage III Colon CancerFang-Shu Ou, Daniel J Walden, Joseph J Larson, et al.

Journal of Gastrointestinal Oncology|November 16, 2023

Identification of an optimal mutant allele frequency to detect activating KRAS, NRAS, and BRAF mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomasBennett A Caughey, Kumiko Umemoto, Michelle F Green, et al.

Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

The Oncologist|June 6, 2019

A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal CancerMohamad Bassam Sonbol, Raed Benkhadra, Zhen Wang, et al.

Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2023

Changes in Prescribing Patterns in Stage III Colon CancerFang-Shu Ou, Daniel J Walden, Joseph J Larson, et al.

Journal of Gastrointestinal Oncology|November 16, 2023

Identification of an optimal mutant allele frequency to detect activating KRAS, NRAS, and BRAF mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomasBennett A Caughey, Kumiko Umemoto, Michelle F Green, et al.

Pageof 1